TITLE:
A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

CONDITION:
Psoriasis

INTERVENTION:
NONE

SUMMARY:

      This was a multicenter, prospective, 5-year surveillance study of approximately 5000
      Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500
      comparison patients who were treated with a biologic therapy other than Raptiva) with
      chronic moderate to severe plaque psoriasis who were candidates for treatment with Raptiva.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: N/A to N/A
Criteria:

        Inclusion Criteria:

          -  Have ever had a physician's diagnosis of chronic moderate to severe plaque psoriasis
             and be a candidate for treatment with Raptiva

          -  Are being treated with or initiating Raptiva therapy at the time of enrollment

          -  Be able to provide written informed consent

          -  Be willing and able to fully to participate for the duration of patient follow-up (5
             years)

        Exclusion Criterion:

          -  Have previously received at least one dose of Raptiva and are not currently using or
             restarting treatment with Raptiva at the time of enrollment
      
